Clinical Case Presentation: A 66-Year-Old Woman with ER+ HER2+ Invasive Ductal Carcinoma and Brain Metastases

Video

Sara Hurvitz, MD, presents the case of a 66-year-old woman with ER+ HER2+ invasive ductal carcinoma and brain metastases.

Related Videos
Experts on MM
A panel of 4 experts on multiple myeloma seated at a long table
Experts on MM
A panel of 4 experts on multiple myeloma seated at a long table
Experts on NSCLC
Experts on NSCLC
Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Related Content
The use of artificial intelligence may help determine how breast cancer tumors develop resistance to certain therapies, notes Rakhshanda Rahman, MD, FRCS, FACS.

More Screening Advocacy Is Needed to Improve Breast Cancer Surgery Outcomes

November 27th 2023
Article

The use of artificial intelligence may help determine how breast cancer tumors develop resistance to certain therapies, notes Rakhshanda Rahman, MD, FRCS, FACS.

Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.

Experts Discuss Differences in Radiotherapy Outcomes in BRCA+ Breast Cancer

October 30th 2023
Podcast

Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.

FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer

FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer

November 16th 2023
Article

Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment

May 8th 2023
Podcast

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Investigators note that prospective research is needed to confirm the efficacy of vitamin D supplements in preventing chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Lack of Vitamin D may Increase Chemo-Induced Neuropathy Risk in Breast Cancer

November 8th 2023
Article

Investigators note that prospective research is needed to confirm the efficacy of vitamin D supplements in preventing chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Investigators are assessing rhenium obisbemeda as a treatment for breast cancer harboring leptomeningeal metastases as part of the phase 1/2a ReSPECT-LM trial.

186Re Obisbemeda Earns FDA ODD in Leptomeningeal Metastatic Breast Cancer

November 6th 2023
Article

Investigators are assessing rhenium obisbemeda as a treatment for breast cancer harboring leptomeningeal metastases as part of the phase 1/2a ReSPECT-LM trial.